IP Library Granted Patent US 8,318,429
Granted Patent B2
US 8,318,429 · App. 13/282,975 · Granted Nov 27, 2012

Genetic markers of schizophrenia

Assignee: University of Louisville Research Foundation, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,318,429
App. No.
13/282,975
Granted
Nov 27, 2012
Kind
B2
Abstract

The invention includes method of determining if a subject has a genetic predisposition to clinically diagnosed schizophrenia (SZ), schizotypal personality disorder (SPD), and/or schizoaffective disorder (SD).

Claims (26)

1. A method of identifying a human subject's risk of developing schizophrenia, the method comprising:

determining a SH3 and multiple ankyrin repeat domains 3 gene (SHANK3) haplotype of the subject, wherein the SHANK3 haplotype comprises alleles of single nucleotide polymorphism rs9616816 and single nucleotide polymorphism rs6010063; and

identifying the subject as a human subject having an increased risk of developing schizophrenia when the haplotype comprises an “A” allele at said single nucleotide polymorphism rs9616816 and an “A” allele at said single nucleotide polymorphism rs6010063, or identifying the subject as a human subject having a decreased risk of developing schizophrenia when the haplotype comprises a “G” allele at said single nucleotide polymorphism rs9616816 and a “G” allele at said single nucleotide polymorphism rs6010063.

2. The method of claim 1 , wherein said determining the SHANK3haplotype comprises:

obtaining a sample comprising genomic DNA from the subject; and

determining the identities of the alleles of single nucleotide polymorphism rs9616816and single nucleotide polymorphism rs6010063.

3. The method of claim 2 , wherein the sample is obtained from the subject by a health care provider.

4. The method of claim 2 , wherein the sample is provided by the subject without the assistance of a health care provider.

5. The method of claim 1 , further comprising determining the presence or absence of one or more additional markers associated with schizophrenia in the subject.

6. The method of claim 1 , wherein the subject has one or more risk factors associated with schizophrenia.

7. The method of claim 6 , wherein said one or more of the risk factors associated with schizophrenia include: the subject has a relative with schizophrenia; the subject has eye tracking dysfunction; the subject has deficits in working memory; or the subject has mixed-handedness.

8. The method of claim 6 , wherein the risk factors associated with schizophrenia include: the subject has one or more relatives who have or had schizophrenia and said one or more relatives include grandparents, parents, uncles, aunts, siblings, or children of the subject.

9. The method of claim 1 , wherein the subject is a child, a fetus, or an embryo, and one of the relatives of the subject has schizophrenia.

10. A method of identifying a human subject's risk of developing schizophrenia, the method comprising:

determining a SH3 and multiple ankyrin repeat domains 3 gene (SHANK3) haplotype of the subject, wherein the SHANK3 haplotype comprises an allele of single nucleotide polymorphism rs9616816; and

identifying the subject as a human subject having an increased risk of developing schizophrenia when the haplotype comprises an “A” allele at said single nucleotide polymorphism rs9616816.

11. The method of claim 10 , wherein said determining the SHANK3 haplotype comprises:

obtaining a sample comprising genomic DNA from the subject; and

determining the identity of the allele of single nucleotide polymorphism rs9616816.

12. The method of claim 11 , wherein the sample is obtained from the subject by a health care provider.

13. The method of claim 11 , wherein the sample is provided by the subject without the assistance of a health care provider.

14. The method of claim 10 , further comprising determining the presence or absence of one or more additional markers associated with schizophrenia in the subject.

15. The method of claim 10 , wherein the subject has one or more risk factors associated with schizophrenia.

16. The method of claim 15 , wherein said one or more of the risk factors associated with schizophrenia include: the subject has a relative with schizophrenia; the subject has eye tracking dysfunction; the subject has deficits in working memory; or the subject has mixed-handedness.

17. The method of claim 15 , wherein the risk factors associated with schizophrenia include: the subject has one or more relatives who have or had schizophrenia and said one or more relatives include grandparents, parents, uncles, aunts, siblings, or children of the subject.

18. The method of claim 10 , wherein the subject is a child, a fetus, or an embryo, and one of the relatives of the subject has schizophrenia.

Assignments (3)
CONFIRMATORY LICENSE Recorded Dec 26, 2012
From: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 029539/0591 →
CORRECTIVE ASSIGNMENT TO CORRECT THE SERIAL NUMBER AND RE-RECORD TO REMOVE 11/279,339 PREVIOUSLY RECORDED ON REEL 027134 FRAME 0038. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 30, 2012
From: BRENNAN, MARK DAVID; PHILLIPS, D. KAY
To: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
Reel/Frame 027615/0679 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 27, 2011
From: BRENNAN, MARK DAVID; PHILLIPS, D. KAY
To: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
Reel/Frame 027134/0038 →
Priority Claims (1)
WO PCT/US2007/078399 · Sep 13, 2007 · international
Continuity (3)
Division 11859168 · Sep 21, 2007
Provisional Application 60948392 · Jul 6, 2007
Related Publication 20120040351A1 · Feb 16, 2012